A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Ascendis Pharma Endocrinology Division A/S
Summary
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Eligibility
- Age range
- 1–18 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Paediatric patients with GHD who are on treatment with lonapegsomatropin * Patients being clinically managed in Europe or the USA * Appropriate written informed consent/assent as applicable for the age of the patient * Patients willing to comply with follow-up requirements of the study Exclusion Criteria: * Patients participating in any interventional clinical trial for short stature * Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment * Patients for whom treatment with lonapegsomatropin is contraindicated * Patients with clo…
Interventions
- DrugNo intervention
No intervention
Locations (27)
- Ascendis Investigational SitePhoenix, Arizona
- Ascendis Investigational SiteOrange, California
- Ascendis Investigational SiteSacramento, California
- Ascendis Investigational SiteSan Francisco, California
- Ascendis Pharma Investigational SiteCentennial, Colorado
- Ascendis Investigational SiteWashington D.C., District of Columbia